Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1253689/000155837019001537/glyc-20181231x10k.htm
November 2023
August 2023
May 2023
April 2023
March 2023
March 2023
March 2023
February 2023
November 2022
October 2022
Document and Entity Information - USD ($) $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2018 | Feb. 28, 2019 | Jun. 30, 2018 | |
Document And Entity Information [Abstract] | |||
Document Type | 10-K | ||
Amendment Flag | false | ||
Document Period End Date | Dec. 31, 2018 | ||
Document Fiscal Year Focus | 2018 | ||
Document Fiscal Period Focus | FY | ||
Entity Registrant Name | GLYCOMIMETICS INC | ||
Entity Central Index Key | 0001253689 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Filer Category | Accelerated Filer | ||
Entity Small Business | true | ||
Entity Emerging Growth Company | true | ||
Entity Ex Transition Period | true | ||
Entity Common Stock, Shares Outstanding | 43,168,969 | ||
Entity Public Float | $ 538.3 |
Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1253689/000155837019001537/glyc-20181231x10k.htm
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Glycomimetics Inc.
Glycomimetics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:
Rating
Learn More![]()
In assessing cash used in operating activities, we consider several principal factors: (i) net loss for the period; (ii) adjustments for non-cash charges including stock-based compensation expense and depreciation and amortization of property and equipment; and (iii) the extent to which receivables, accounts payable and other liabilities, or other working capital components increase or decrease.
These prepaid expenses were offset by a decrease in costs for clinical expenses related to uproleselan and GMI-1359.
At contract inception, once the contract is determined to be within the scope of Topic 606, we assess the goods or services promised within each contract and identify, as a performance obligation, and assess whether each promised good or service is distinct.
In addition, personnel-related and stock-based compensation expenses increased in 2017 by approximately $0.9 million due to an increase in labor-related costs and stock-based compensation expense.
In March 2016, we entered into an at-the-market sales agreement with Cowen to sell shares of our common stock having an aggregate offering price of up to $40.0 million through Cowen acting as our sales agent.
We received an additional $19.7...Read more
Other income increased by $2.6...Read more
We are also eligible to...Read more
We cannot assure you that...Read more
We have selected the Black-Scholes-Merton...Read more
To date, we have financed...Read more
To determine revenue recognition for...Read more
Net cash provided by financing...Read more
Financing Activities Net cash provided...Read more
Personnel-related and stock-based compensation expenses...Read more
The foregoing table does not...Read more
Personnel-related and stock-based compensation expenses...Read more
Effective January 1, 2018, we...Read more
We record costs for some...Read more
The license also covers specified...Read more
Under the agreement, Pfizer made...Read more
Royalties: For arrangements that include...Read more
The following table summarizes our...Read more
The IPO provided us with...Read more
In September 2017, we entered...Read more
In May 2017, the European...Read more
Substantially all of our revenue...Read more
The transaction price is then...Read more
If we raise additional funds...Read more
The capitalized amounts are expensed...Read more
We have generated cumulative revenue...Read more
We expect our research and...Read more
In December 2018, at the...Read more
We will determine which programs...Read more
Our primary uses of capital...Read more
Our initial research and development...Read more
Prior to our IPO, we...Read more
Under Topic 606, an entity...Read more
Payments for these activities are...Read more
While our significant accounting policies...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Material Contracts, Statements, Certifications & more
Glycomimetics Inc provided additional information to their SEC Filing as exhibits
Ticker: GLYC
CIK: 1253689
Form Type: 10-K Annual Report
Accession Number: 0001558370-19-001537
Submitted to the SEC: Wed Mar 06 2019 3:30:07 AM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Monday, December 31, 2018
Industry: Pharmaceutical Preparations